Skip to search formSkip to main contentSkip to account menu

AMN107

Known as: AMN 107 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

nilotinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q 
2012
2012
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients 
2010
2010
Inhibition of JAK–STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells
Inhibition of JAK–STAT signaling by TG101348: a novel mechanism for inhibition of KIT D816V-dependent growth in mast cell… 
2009
2009
The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication.
2008
2008
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib
Findings of this study suggest that monitoring the actual BCR-ABL inhibition in nilotinib treated patients may be useful for… 
2007
2007
Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
2006
2006
Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed…
3095 Background: AMN107, a selective and potent inhibitor of Bcr-Abl tyrosine kinase, has demonstrated activity against imatinib… 
Review
2006
Review
2006
The Second Generation of BCR-ABL Tyrosine Kinase Inhibitors
Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia… 
2006
2006
Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous…
Nilotinib is a novel, highly selective oral Bcr-Abl inhibitor which is approximately 30-fold more potent than imatinib. High… 
2006
2006
A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).
9545 Background: Although imatinib induces durable clinical benefit in pts with metastatic GIST, resistance may emerge. AMN107 is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)